- Home
- CHGG vs PRLD Comparison
CHGG vs PRLD Comparison
Compare CHGG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHGG | PRLD |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.6M | 69.1M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHGG | PRLD |
|---|---|---|
| Price | $0.57 | $3.41 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | ★ 1.0M | 315.8K |
| Earning Date | 05-11-2026 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.15 | 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,908,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $0.44 | $0.61 |
| 52 Week High | $1.89 | $4.19 |
Technical Indicators
Market Signals| Indicator | CHGG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.41 | 61.49 |
| Support Level | $0.53 | $0.99 |
| Resistance Level | $0.83 | $4.19 |
| Average True Range (ATR) | 0.04 | 0.37 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 7.75 | 58.90 |
Price Performance
Historical ComparisonAbout CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.